Doxribtimine
Doxribtimine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
98 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 4 | — | 2 | 5 | 13 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 3 | — | 1 | 2 | 7 |
| Lipodystrophy | D008060 | HP_0009125 | E88.1 | — | 2 | — | 1 | 1 | 4 |
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | — | 1 | — | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 6 | 8 | 2 | — | — | 15 |
| Colorectal neoplasms | D015179 | — | — | 7 | 5 | 1 | — | 2 | 13 |
| Vaccinia | D014615 | — | — | 8 | 7 | 1 | — | — | 13 |
| Neoplasms | D009369 | — | C80 | 7 | 1 | 1 | — | 1 | 9 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 3 | 5 | 1 | — | — | 9 |
| Leukemia | D007938 | — | C95 | 1 | — | 1 | — | — | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | — | 1 | — | — | 1 |
| Lymphoid leukemia | D007945 | — | C91 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 4 | 5 | — | — | — | 8 |
| Melanoma | D008545 | — | — | 5 | 2 | — | — | 1 | 6 |
| Adenocarcinoma | D000230 | — | — | 1 | 4 | — | — | — | 5 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | 2 | 4 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 1 | — | — | 2 | 4 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 2 | — | — | — | 3 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | 1 | — | — | 1 | 3 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 3 | — | — | — | 3 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 2 | — | — | 1 | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 2 | — | — | 1 | 3 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 2 | — | — | — | 2 | 4 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | 1 | 2 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | 1 | 2 |
| Tetralogy of fallot | D013771 | HP_0001636 | Q21.3 | 1 | — | — | — | 1 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma | D002294 | — | — | 1 | — | — | — | — | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 8 | 8 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | — | — | 2 | 2 |
| Wasting syndrome | D019282 | — | — | — | — | — | — | 1 | 1 |
| Cachexia | D002100 | HP_0004326 | R64 | — | — | — | — | 1 | 1 |
| Triple negative breast neoplasms | D064726 | — | — | — | — | — | — | 1 | 1 |
| Essential thrombocythemia | D013920 | — | D47.3 | — | — | — | — | 1 | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | — | — | — | 1 | 1 |
| Thrombocytosis | D013922 | HP_0001894 | D75.83 | — | — | — | — | 1 | 1 |
| Ependymoma | D004806 | — | — | — | — | — | — | 1 | 1 |
| Primitive neuroectodermal tumors | D018242 | — | — | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Doxribtimine |
| INN | doxribtimine |
| Description | 1-(2-Deoxypentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione is a pyrimidine 2'-deoxyribonucleoside. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O |
Identifiers
| PDB | — |
| CAS-ID | 50-89-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL52609 |
| ChEBI ID | 17748 |
| PubChem CID | 1134 |
| DrugBank | DB04485 |
| UNII ID | VC2W18DGKR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
104 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use